Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 or older~* Sever SCD phenotypes (Hb SS and Sβthalassemia0)~* A positive response to cough/wheeze questions~Exclusion Criteria:~* Patient carries a physician diagnosis of asthma~* Patient is prescribed asthma medications~* Patient is currently having a painful crisis (as defined by validated pain diary questions)~* Patient has acute respiratory symptoms~* Known hypersensitivity to milk proteins~* Meets criteria for our operational diagnosis of asthma~* More than 15 ED visits for pain over the preceding 12 months~* Admitted or discharged from the hospital for SCD pain within the last 7 days

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate (Type: EXPERIMENTAL): 1 puff daily (220mcg) for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).